The role of FDG PET in the management of lymphoma: what is the evidence base?
[18F]Fluorodeoxyglucose positron emission tomography (18F-FDG PET) is playing an increasing role in the management of both Hodgkin and non-Hodgkin lymphoma, offering potential advantages in the accuracy of disease assessment at a number of points in the management pathway. This review evaluates the current level of confidence in the use of PET technology in (1) initial staging, (2) the assessment of early response to chemotherapy, (3) the assessment of residual masses at completion of initial treatment, (4) follow-up, and (5) radiotherapy planning.
Kirby
Anna M
AM
Department of Clinical Oncology, Guy's and St Thomas' NHS Trust, London, UK. annakirby@doctors.org.uk
Mikhaeel
N George
NG
D002986:Clinical Trials as Topic / Q000639:trends*; D019317:Evidence-Based Medicine / Q000639:trends*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000628:therapy*; D049268:Positron-Emission Tomography / Q000379:methods / Q000639:trends*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18